Testing plonmarlimab for blood cell overactivation in people with rheumatic disease
Part of Blood & lymphatic, Immune system & allergy clinical trials.
This trial tests a new drug called plonmarlimab for people with a rheumatic (joint or immune) disease who also have a dangerous overreaction of their immune system called HLH (or MAS). The goal is to see if the drug can help when high-dose steroids have not worked or are not an option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 16 to 80 years old.
- You must have a rheumatic or immune disease (like lupus, arthritis, or similar).
- You must have been diagnosed with HLH (a severe immune overreaction) that hasn't responded to high-dose steroids or you can't use steroids.
- You cannot have HLH caused by an infection, cancer, or other treatments like CAR-T cells.
- You cannot have another active cancer (except some minor skin or localized cancers) or a history of blood cancers.
- You cannot have severe heart, lung, or kidney problems, or uncontrolled infections like tuberculosis or hepatitis.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of medicines (the GO regimen) for people with hemophagocytic lymphohistiocytosis (HLH) that is either newly diagnosed, has come back, or hasn't responded to other treatments. It aims to see if this approach can help when a stem cell transplant isn't an option right now.
This trial tests a combination of five drugs to treat a rare blood cancer called NK/T-cell lymphoma that has triggered an abnormal immune response (hemophagocytic lymphohistiocytosis). The goal is to control both the cancer and the harmful immune reaction.
This trial studies whether a specific treatment (a chemotherapy-based induction plan plus a PD-1 antibody) can improve outcomes in adults with lymphoma-associated HLH caused by Epstein-Barr virus (EBV). It aims to better control the overactive immune disease driving HLH and lymphoma.
This study tests a new drug called HRS-3005 in patients with B-cell blood cancers that have come back or stopped responding to prior treatment. The trial aims to find the right dose and understand how well the drug works and what side effects it causes.
This trial looks for a DNA marker in people with HLH caused by lymphoma. It may help doctors better confirm the cause of HLH and guide treatment decisions.
This trial tests two drugs, emapalumab and ruxolitinib, in people with hemophagocytic lymphohistiocytosis (HLH), a condition where the immune system becomes overactive. The goal is to find the safest and most effective doses of these medications.
Hear when a new Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.